Trials / Recruiting
RecruitingNCT01522183
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Detailed description
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
Conditions
Timeline
- Start date
- 2013-03-18
- Primary completion
- 2031-01-01
- Completion
- 2031-01-01
- First posted
- 2012-01-31
- Last updated
- 2025-09-16
Locations
141 sites across 17 countries: United States, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Poland, Russia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01522183. Inclusion in this directory is not an endorsement.